Mohammad Alashqar Shares Fitusiran Review for Hemophilia A and B, With or Without Inhibitors
Mohammad Alashqar, Postdoctoral Pharmacotherapy Research Fellow at The Ohio State University College of Pharmacy, shared on LinkedIn:
”Grateful to share that my review paper, “Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors,” has been published online today (12/26)
Sincere thanks to everyone who supported me throughout this journey—especially Dr. Milap Nahata for his mentorship, guidance, and invaluable feedback.
This work would not have been possible without such support.
Looking forward to continuing contributions to hemophilia and thrombosis research.”
Read the full article here.
Article: Fitusiran: A Novel Antithrombin-Targeting Therapy for Hemophilia A and B, With or Without Inhibitors
Authors: Mohammad Alashqar, Milap Nahata
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 12:46Rosa Hart: Inside Pediatric Stroke Recovery with Dr. Catherine Schuster
-
Apr 14, 2026, 12:39Gonzalo Ladreda: Innovation in Stroke Care Is About Timing, Integration, and Real-World Usability
-
Apr 14, 2026, 12:30Roy P.C. Kessels: Stroke’s Cognitive Impact on Young Adults Is Significant and Often Overlooked
-
Apr 14, 2026, 12:22Mehari Gebreyohanns: New Insights on Wake-Up Strokes from Emergency Settings in Texas and Louisiana
-
Apr 14, 2026, 12:08Enrico Ferro: Comparative Study Raises Questions on PFA Safety in AF at EHRA 2026
-
Apr 14, 2026, 11:39Prachi Patel: How B Vitamins and Large-Scale Research Are Shaping Stroke Prevention
-
Apr 14, 2026, 11:28Jamie Brannigan: Help Shape the Future of Brain-Computer Interfaces in Stroke and Neurological Care
-
Apr 14, 2026, 11:18David Ferri: A Fontan Conduit Thrombosis Managed With an Innovative Catheter-Based Thrombectomy
-
Apr 14, 2026, 09:51Understanding Bleeding Disorder of Unknown Cause – EHC